دورية أكاديمية
أعرض في EDS

Transcutaneous tibial nerve stimulation: 2 years follow-up outcomes in the management of anticholinergic refractory overactive bladder.

التفاصيل البيبلوغرافية
العنوان: Transcutaneous tibial nerve stimulation: 2 years follow-up outcomes in the management of anticholinergic refractory overactive bladder.
المؤلفون: Leroux PA; Department of Urology, Angers University Hospital, 4 rue Larrey, 49100, Angers, France. pa.l3rx@gmail.com., Brassart E; Department of Urology, Angers University Hospital, 4 rue Larrey, 49100, Angers, France., Lebdai S; Department of Urology, Angers University Hospital, 4 rue Larrey, 49100, Angers, France., Azzouzi AR; Department of Urology, Angers University Hospital, 4 rue Larrey, 49100, Angers, France., Bigot P; Department of Urology, Angers University Hospital, 4 rue Larrey, 49100, Angers, France., Carrouget J; Department of Urology, Angers University Hospital, 4 rue Larrey, 49100, Angers, France.
المصدر: World journal of urology [World J Urol] 2018 Sep; Vol. 36 (9), pp. 1455-1460. Date of Electronic Publication: 2018 Apr 09.
نوع المنشور: Journal Article; Observational Study
اللغة: English
بيانات الدورية: Publisher: Springer International Country of Publication: Germany NLM ID: 8307716 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1433-8726 (Electronic) Linking ISSN: 07244983 NLM ISO Abbreviation: World J Urol Subsets: MEDLINE
أسماء مطبوعة: Original Publication: [Berlin ; New York] : Springer International, 1983-
مواضيع طبية MeSH: Tibial Nerve* , Transcutaneous Electric Nerve Stimulation*/statistics & numerical data, Urinary Bladder, Overactive/*therapy, Adult ; Aged ; Aged, 80 and over ; Cholinergic Antagonists/therapeutic use ; Drug Resistance ; Female ; Follow-Up Studies ; Humans ; Male ; Middle Aged ; Prospective Studies ; Time Factors ; Treatment Outcome
مستخلص: Purpose: To evaluate long-term use, efficacy and tolerability of transcutaneous tibial nerve stimulation (TTNS) in the treatment of refractory overactive bladder (OAB).
Methods: We performed a prospective observational study and included all patients treated in a single center for OAB persisting after first-line anticholinergic treatment, with ≥ 24 months follow-up. The protocol consisted of daily stimulation at home. The primary outcome was treatment persistence. Amelioration was defined as an improvement in urinary symptom profile (USP) score.
Results: We assessed 84 consecutive patients. After a mean follow-up of 39.3 months and a mean treatment use of 8.3 months, almost two-thirds of patients (71.8%) had discontinued TTNS. Treatment continuation was > 12 months for 28 patients (33.3%) and > 18 months for 16 patients (19%). TTNS was successful following 3 months of treatment in 60 (71%) patients. Mean USP score stayed significantly lower than baseline until 12 months of treatment, but was not significant anymore after 18 months. Discontinuation therapy reasons were a lack of sufficient symptom relief for 59 (70%) patients, compliance difficulty for 5 (6%) patients and becoming asymptomatic for 6 (8%) patients. No serious adverse events occurred.
Conclusions: The present study confirms the utility of TTNS as a treatment option for patients with resistant OAB. In the long-term use, few patients continued with therapy, mostly because of a decreased effectiveness with time.
References: Neurourol Urodyn. 2003;22(3):227-32. (PMID: 12707873)
Cochrane Database Syst Rev. 2016 Dec 09;12:CD010098. (PMID: 27935011)
Urology. 2000 Nov 1;56(5):766-71. (PMID: 11068296)
Eur Urol. 2006 Dec;50(6):1306-14; discussion 1314-5. (PMID: 17049716)
Cochrane Database Syst Rev. 2012 Jan 18;1:CD005429. (PMID: 22258963)
Urol Nurs. 2009 Jan-Feb;29(1):30-4. (PMID: 19331273)
J Urol. 2001 Apr;165(4):1193-8. (PMID: 11257669)
Neurourol Urodyn. 2011 Mar;30(3):306-11. (PMID: 21305588)
Neurourol Urodyn. 2010;29(1):4-20. (PMID: 19941278)
J Urol. 2013 Jun;189(6):2194-201. (PMID: 23219541)
J Manag Care Pharm. 2008 Apr;14(3):291-301. (PMID: 18439051)
World J Urol. 2014 Feb;32(1):179-84. (PMID: 23749315)
Urology. 2008 Apr;71(4):646-56. (PMID: 18313122)
J Urol. 2009 Sep;182(3):1055-61. (PMID: 19616802)
Int Urogynecol J. 2010 Sep;21(9):1065-70. (PMID: 20458465)
Int Urogynecol J. 2014 Aug;25(8):1065-9. (PMID: 24599180)
J Urol. 2003 Jun;169(6):2210-5. (PMID: 12771752)
Int Urol Nephrol. 2015 Oct;47(10):1619-27. (PMID: 26347077)
Neurourol Urodyn. 2010;29(1):213-40. (PMID: 20025020)
فهرسة مساهمة: Keywords: Detrusor overactivity; Overactive bladder; Transcutaneous tibial nerve stimulation; USP
المشرفين على المادة: 0 (Cholinergic Antagonists)
تواريخ الأحداث: Date Created: 20180411 Date Completed: 20190318 Latest Revision: 20190318
رمز التحديث: 20231215
DOI: 10.1007/s00345-018-2296-5
PMID: 29633085
قاعدة البيانات: MEDLINE
الوصف
تدمد:1433-8726
DOI:10.1007/s00345-018-2296-5